Stevanato Group reported a robust first quarter for 2025, with revenue increasing 9% year-over-year to €256.6 million, or 8% on a constant currency basis. This growth was primarily driven by an 11% surge in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, reaching €220.8 million.
High-value solutions (HVS) revenue grew to €110.3 million, representing 43% of total revenue, fueled by strong demand for high-value syringes and increased capacity at the Latina and Fishers facilities. The consolidated gross profit margin improved by 80 basis points to 27.2%, with the BDS segment's gross profit margin expanding by 420 basis points to 31.3%.
The company maintained its fiscal year 2025 revenue guidance of €1.160 billion to €1.190 billion. However, it updated its adjusted EBITDA and adjusted diluted EPS guidance to account for an estimated €4.5 million tariff-related impact on operating profit, or approximately €0.01 of adjusted diluted EPS. Stevanato Group generated €29.7 million in free cash flow for the quarter, a notable improvement.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.